Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.63 |
| ▸ | HTR3B | O95264 | 1/20 | 0.63 |
| ▸ | HTR5A | P47898 | 1/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568851 | 0.94 | HTR3A (0.57) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL7280369 | 0.87 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2230474 | 0.87 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2230467 | 0.87 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| Hydrochloric Acid SCHEMBL9602943 | 0.86 | MAPK1 (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| Hydrochloric Acid SCHEMBL7290608 | 0.86 | MAPK1 (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| Hydrochloric Acid SCHEMBL7290599 | 0.86 | MAPK1 (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2229332 | 0.85 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL2229328 | 0.85 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR5AHTR3D | |
| SCHEMBL1567955 | 0.82 | CHRNA7 (0.52) | HTR3AHTR3EHTR3BHTR5AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112119-A1 | AZABICYCLOOCTYL-QUINAZOLONE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112119-A1 | AZABICYCLOOCTYL-QUINAZOLONE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA5, CHRNA6, CHRNA3 | HTR3A 111/4885HTR3E 217/4885HTR3B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.